Tracked deals
11
11 tracked deals across 2020-2026.
Biotechnology Buyers & Acquisitions in Texas
Buyer mix
Strategic-led
9 strategic · 3 pe
Top trend
Volume peaked in 2023
3 tracked deals announced in 2023.
Primary Insight
What Stands Out
- Texas-based targets show a mix of pre-clinical platform growth (e.g., dual-payload ADC development) and clinical-stage programs (e.g., FDA-approved rare disease therapy).
- Recurring buyer themes include platform buildouts and capability expansion, such as cell-therapy CDMO capacity and diagnostic manufacturing.
- Pharma acquirers represented include Eli Lilly and Company, Biogen Inc., and Bristol Myers Squibb.
- Investment-backed life-science operators also appear frequently, including VION Biosciences and 3D Systems.
- Deal structures vary across the set: definitive mergers, stock-for-stock acquisitions, and transactions that combine upfront value with milestone payments.
Build a buyer list for your Biotechnology deal
Find buyers actively acquiring biotechnology companies.
Find buyers like these for your dealBuyer Snapshot
Top Buyers
Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.
| Buyer | # Deals | Focus | Type |
|---|---|---|---|
| 3D Systems | 1 | Public additive-manufacturing company providing hardware,... | Strategic |
| Aileron Therapeutics, Inc. | 1 | Nasdaq-listed clinical-stage biopharmaceutical company fo... | Strategic |
| Biogen Inc. | 1 | Global biotechnology company focused on discovery, develo... | Strategic |
| Bristol Myers Squibb | 1 | Global biopharmaceutical company focused on discovering, ... | Strategic |
| Colossal Biosciences | 1 | Biotechnology company focused on de‑extinction, species r... | Strategic |
| Eli Lilly and Company | 1 | Global pharmaceutical company expanding its oncology and ... | Strategic |
| Global Cord Blood Corporation | 1 | Cord blood banking operator providing cord blood collecti... | Strategic |
| Great Point Partners | 1 | Healthcare-focused private equity firm and majority inves... | PE |
| HealthQuest Capital | 1 | Growth-stage / healthcare-focused private investment firm... | PE |
| Iron Path Capital | 1 | Private equity firm focused on building businesses in hea... | PE |
Acquisition Volume in Biotechnology in Texas by Year
Last 7 years
Actual
Full-year estimate
Supporting Data
Recent Transactions
-
April 14, 2026
- Buyer
- Eli Lilly and Company
- Target
- CrossBridge Bio
- Industry
- Biotechnology
- Location
- Texas, United States
- Type
- Buyout
Eli Lilly and Company has entered into a definitive agreement to acquire CrossBridge Bio, a Houston-based pre-clinical biotechnology company developing next-generation dual-payload antibody-drug conjugates (ADCs). The deal provides for up to $300 million in total consideration, including upfront and milestone-based payments, to advance CrossBridge Bio’s TROP2-targeting TOP1i/ATRi ADC platform led by CBB-120.
-
March 26, 2026
- Buyer
- Pulmatrix, Inc., RCM Eos PIPE HOLDINGS LLC, Rapha Capital Management, LLC
- Target
- Eos SENOLYTIX, Inc.
- Industry
- Biotechnology
- Location
- Texas, United States
- Type
- Buyout
Pulmatrix, Inc. has entered into a definitive merger agreement to acquire Eos SENOLYTIX, Inc. Upon closing, the combined company will operate as Eos SENOLYTIX, Inc. and is expected to trade on Nasdaq under the ticker EOSX.
-
November 7, 2025
- Buyer
- Colossal Biosciences
- Target
- Viagen Pets and Equine
- Industry
- Biotechnology
- Location
- Texas, United States
- Type
- Buyout
Colossal Biosciences has acquired Viagen Pets and Equine, a Texas-based leader in animal cloning, cryopreservation, and genetic preservation, which will operate as a wholly owned subsidiary under its existing leadership. The deal expands Colossal’s de‑extinction and species preservation platform, bringing Viagen’s cloning expertise, biobanking capabilities and a ~25‑person team into Colossal’s conservation pipeline.
-
October 7, 2024
- Buyer
- HealthQuest Capital, Great Point Partners
- Target
- Cellipont Bioservices
- Industry
- Biotechnology
- Location
- Texas, United States
- Type
- Growth capital
Cellipont Bioservices named Darren Head as CEO and announced a minority growth equity investment from HealthQuest Capital, with majority investor Great Point Partners also participating. The capital and leadership transition are intended to support Cellipont’s expansion of cell-therapy CDMO capabilities and operational growth.
-
August 29, 2024
- Buyer
- VION Biosciences, Iron Path Capital
- Target
- Ansh Labs
- Industry
- Biotechnology
- Location
- Texas, United States
- Type
- Addon
VION Biosciences, the life-science platform backed by Iron Path Capital, has acquired Ansh Labs, an immunoassay development and reagent manufacturer based in Houston, Texas. The add-on expands VION's diagnostics capabilities — adding GMP IVD manufacturing and ISO 13485 certification — and broadens the platform's product and service offerings for clinical diagnostics, research, and pharmaceutical development.
-
October 31, 2023
- Buyer
- Aileron Therapeutics, Inc.
- Target
- Lung Therapeutics, Inc.
- Industry
- Biotechnology
- Location
- Texas, United States
- Type
- Buyout
Aileron Therapeutics, Inc. (NASDAQ: ALRN) completed a stock-for-stock acquisition of Lung Therapeutics, Inc., bringing the clinical-stage pulmonary and fibrosis-focused pipeline (including lead candidate LTI-03) into Aileron's portfolio. Immediately after the acquisition Aileron arranged a private placement led by Bios Partners (with participation from Nantahala Capital and others) to raise approximately $18 million to fund ongoing development, including a Phase 1b trial of LTI-03.
-
July 28, 2023
- Buyer
- Biogen Inc.
- Target
- Reata Pharmaceuticals, Inc.
- Industry
- Biotechnology
- Location
- Texas, United States
- Type
- Buyout
Biogen Inc. agreed to acquire Reata Pharmaceuticals, Inc. for $172.50 per share in cash, representing an enterprise value of approximately $7.3 billion. The acquisition adds Reata's FDA-approved SKYCLARYS (omaveloxolone) for Friedreich's ataxia to Biogen's rare disease portfolio and is expected to be significantly accretive to Biogen's Non-GAAP diluted EPS beginning in 2025; the transaction was anticipated to close in Q4 2023.
-
April 28, 2023
- Buyer
- Yotta Acquisition Corporation
- Target
- NaturalShrimp Incorporated
- Industry
- Biotechnology
- Location
- Texas, United States
- Type
- Buyout
NaturalShrimp, Incorporated announced it has signed a definitive business combination agreement with Nasdaq-listed Yotta Acquisition Corporation to merge the companies via Yotta Merger Sub. The combined company is expected to accelerate commercialization and ramp up production of NaturalShrimp’s farm-to-table, sushi-grade shrimp, with the transaction supported by up to $105 million in net cash from Yotta’s trust (subject to redemptions) and expected listing on Nasdaq post-close.
-
April 29, 2022
- Buyer
- Global Cord Blood Corporation
- Target
- Cellenkos, Inc.
- Seller
- Holders of approximately 95% of Cellenkos outstanding equity interest, GM Precision Medicine (BVI) Limited
- Industry
- Biotechnology
- Location
- Texas, United States
- Type
- Buyout
Global Cord Blood Corporation (GCBC) agreed to acquire 100% of clinical-stage biotech Cellenkos, Inc., and worldwide rights to most of its products (excluding those under an Incyte collaboration). The transaction consideration includes approximately 125 million new shares (as-converted) valued at $11 per share plus $664 million in cash; GCBC said the acquisition expands its capabilities into allogeneic T-reg cell therapies and supports global commercialization and R&D.
-
October 27, 2021
- Buyer
- 3D Systems
- Target
- Volumetric
- Seller
- Volumetric shareholders
- Industry
- Biotechnology
- Location
- Texas, United States
- Type
- Buyout
3D Systems has agreed to acquire Houston-based biofabrication start-up Volumetric for $45 million at closing with up to $355 million in milestone-based earnouts tied to human-application development, creating a new 20,000 sq. ft. regenerative medicine facility in Houston. The acquisition brings Volumetric's light-based bioprinting platform and biomaterials into 3D Systems' life-sciences capabilities and supports an existing joint development program with United Therapeutics.
-
August 24, 2020
- Buyer
- Bristol Myers Squibb
- Target
- Forbius
- Seller
- Forbius
- Industry
- Biotechnology
- Location
- Texas, United States
- Type
- Buyout
Bristol Myers Squibb entered into a definitive agreement to acquire Forbius, a clinical-stage protein engineering company, to obtain its isoform‑selective TGF‑beta 1 & 3 program including lead asset AVID200. The deal includes an upfront payment plus potential milestone payments; Forbius' non‑TGF‑beta assets will be transferred to a newly formed private company retained by Forbius' existing shareholders, and the parties expected to close in Q4 2020 subject to customary conditions.
Build a buyer list for your Biotechnology deal
Find buyers actively acquiring biotechnology companies.
Frequently Asked Questions
Which large pharma buyers are shown in Texas biotechnology acquisitions?
The provided transactions list Eli Lilly and Company, Biogen Inc., and Bristol Myers Squibb as acquirers of Texas-based biotech companies.
What kinds of capabilities do Texas targets bring to acquirers?
Based on the transaction summaries, targets may contribute platform IP (such as ADC or protein engineering), clinical pipelines (including FDA-approved products), and enabling capabilities like diagnostics manufacturing, cell-therapy CDMO services, or bioprinting and biomaterials.
Are these deals limited to a single subsector within biotechnology?
No. The page facts include therapeutics (rare disease, pulmonary/fibrosis, protein engineering), enabling diagnostics and immunoassays, and adjacent biology applications such as animal cloning and biobanking for conservation.
Where are the acquisition activities located?
In the provided transactions, locations are consistently shown as Texas, United States.
Related Acquisition Pages
Biotechnology Buyers & Acquisitions
Biotechnology Buyers & Acquisitions in Canada
Private Equity-Backed Biotechnology Buyers
Biotechnology Acquisitions in 2026
Biotechnology Acquisitions in 2025
Biotechnology Acquisitions in 2024
Biotechnology Acquisitions in 2023
Biotechnology Acquisitions in 2022
Biotechnology Acquisitions in 2021
Acquisitions in Texas
Private Equity-Backed Acquisitions in Texas
Acquisitions in Texas in 2026